Perspective view of allogeneic IgG tumor immunotherapy
Abstract Allogeneic tumors are eradicated by host immunity; however, it is unknown how it is initiated until the report in Nature by Yaron Carmi et al. in 2015. Currently, we know that allogeneic tumors are eradicated by allogeneic IgG via dendritic cells. AlloIgG combined with the dendritic cell st...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-024-03290-9 |
| _version_ | 1797266558467178496 |
|---|---|
| author | Ying Liu Yuanyi Huang Hong-Wei Cui YingYing Wang ZhaoWu Ma Ying Xiang Hong-Yi Xin Jun-Qing Liang Hong-Wu Xin |
| author_facet | Ying Liu Yuanyi Huang Hong-Wei Cui YingYing Wang ZhaoWu Ma Ying Xiang Hong-Yi Xin Jun-Qing Liang Hong-Wu Xin |
| author_sort | Ying Liu |
| collection | DOAJ |
| description | Abstract Allogeneic tumors are eradicated by host immunity; however, it is unknown how it is initiated until the report in Nature by Yaron Carmi et al. in 2015. Currently, we know that allogeneic tumors are eradicated by allogeneic IgG via dendritic cells. AlloIgG combined with the dendritic cell stimuli tumor necrosis factor alpha and CD40L induced tumor eradication via the reported and our proposed potential signaling pathways. AlloIgG triggers systematic immune responses targeting multiple antigens, which is proposed to overcome current immunotherapy limitations. The promising perspectives of alloIgG immunotherapy would have advanced from mouse models to clinical trials; however, there are only 6 published articles thus far. Therefore, we hope this perspective view will provide an initiative to promote future discussion. |
| first_indexed | 2024-04-25T01:02:36Z |
| format | Article |
| id | doaj.art-49d2faa1cfad4a319d7c9c3d57dbe2cd |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-04-25T01:02:36Z |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-49d2faa1cfad4a319d7c9c3d57dbe2cd2024-03-10T12:22:37ZengBMCCancer Cell International1475-28672024-03-0124111310.1186/s12935-024-03290-9Perspective view of allogeneic IgG tumor immunotherapyYing Liu0Yuanyi Huang1Hong-Wei Cui2YingYing Wang3ZhaoWu Ma4Ying Xiang5Hong-Yi Xin6Jun-Qing Liang7Hong-Wu Xin8Department of Radiology, Jingzhou Hospital Affiliated to Yangtze UniversityDepartment of Radiology, Jingzhou Hospital Affiliated to Yangtze UniversityCenter for Breast Cancer, Peking University Cancer Hospital at Inner Mongolia Campus and Affiliated Cancer Hospital of Inner Mongolia Medical UniversityDivision of Life Sciences and Medicine, Department of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaLaboratory of Oncology, School of Basic Medicine, Center for Molecular Medicine, Health Science Center, Yangtze UniversityLaboratory of Oncology, School of Basic Medicine, Center for Molecular Medicine, Health Science Center, Yangtze UniversityThe Doctoral Scientific Research Center, People’s Hospital of LianjiangCenter for Breast Cancer, Peking University Cancer Hospital at Inner Mongolia Campus and Affiliated Cancer Hospital of Inner Mongolia Medical UniversityLaboratory of Oncology, School of Basic Medicine, Center for Molecular Medicine, Health Science Center, Yangtze UniversityAbstract Allogeneic tumors are eradicated by host immunity; however, it is unknown how it is initiated until the report in Nature by Yaron Carmi et al. in 2015. Currently, we know that allogeneic tumors are eradicated by allogeneic IgG via dendritic cells. AlloIgG combined with the dendritic cell stimuli tumor necrosis factor alpha and CD40L induced tumor eradication via the reported and our proposed potential signaling pathways. AlloIgG triggers systematic immune responses targeting multiple antigens, which is proposed to overcome current immunotherapy limitations. The promising perspectives of alloIgG immunotherapy would have advanced from mouse models to clinical trials; however, there are only 6 published articles thus far. Therefore, we hope this perspective view will provide an initiative to promote future discussion.https://doi.org/10.1186/s12935-024-03290-9Allogeneic IgGFcγRDendritic cellAntigen presentationTumor immunotherapy |
| spellingShingle | Ying Liu Yuanyi Huang Hong-Wei Cui YingYing Wang ZhaoWu Ma Ying Xiang Hong-Yi Xin Jun-Qing Liang Hong-Wu Xin Perspective view of allogeneic IgG tumor immunotherapy Cancer Cell International Allogeneic IgG FcγR Dendritic cell Antigen presentation Tumor immunotherapy |
| title | Perspective view of allogeneic IgG tumor immunotherapy |
| title_full | Perspective view of allogeneic IgG tumor immunotherapy |
| title_fullStr | Perspective view of allogeneic IgG tumor immunotherapy |
| title_full_unstemmed | Perspective view of allogeneic IgG tumor immunotherapy |
| title_short | Perspective view of allogeneic IgG tumor immunotherapy |
| title_sort | perspective view of allogeneic igg tumor immunotherapy |
| topic | Allogeneic IgG FcγR Dendritic cell Antigen presentation Tumor immunotherapy |
| url | https://doi.org/10.1186/s12935-024-03290-9 |
| work_keys_str_mv | AT yingliu perspectiveviewofallogeneiciggtumorimmunotherapy AT yuanyihuang perspectiveviewofallogeneiciggtumorimmunotherapy AT hongweicui perspectiveviewofallogeneiciggtumorimmunotherapy AT yingyingwang perspectiveviewofallogeneiciggtumorimmunotherapy AT zhaowuma perspectiveviewofallogeneiciggtumorimmunotherapy AT yingxiang perspectiveviewofallogeneiciggtumorimmunotherapy AT hongyixin perspectiveviewofallogeneiciggtumorimmunotherapy AT junqingliang perspectiveviewofallogeneiciggtumorimmunotherapy AT hongwuxin perspectiveviewofallogeneiciggtumorimmunotherapy |